Prospective, randomized, double-blind, active-controlled, multicenter trial of bivalirudin and un-fractionated heparin in patients undergoing percutaneous coronary interventions. ISAR-REACT-3

Trial Profile

Prospective, randomized, double-blind, active-controlled, multicenter trial of bivalirudin and un-fractionated heparin in patients undergoing percutaneous coronary interventions. ISAR-REACT-3

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Bivalirudin; Heparin
  • Indications Angina pectoris; Cardiovascular disorders; Coronary artery disease; Coronary disorders; Coronary thrombosis; Thrombosis; Unstable angina pectoris
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms ISAR-REACT 3
  • Most Recent Events

    • 11 Feb 2010 Results published in European Heart Journal.
    • 11 Feb 2010 Primary endpoint 'Death rate' has not been met.
    • 11 Feb 2010 Primary endpoint 'Myocardial infarction event rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top